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Abstract In the light of the relationship between the MDR1
G2677T polymorphism and the risk of leukemia remains
inclusive or controversial. For better understanding of the
effect of MDR1 G2677T polymorphism on leukemia risk,
we performed a meta-analysis. Eligible studies were identified
through a search of electronic databases such as PubMed,
Excerpta Medica Database (Embase), Cochrane Library, and
Chinese Biomedical Literature Database (CBM). The associ-
ation between the MDR1 G2677T polymorphism and leuke-
mia risk was conducted by odds ratios (ORs) and 95 %
confidence intervals (95 % CI). A total of seven publications
including eight studies with 1,229 cases and 1,097 controls
were included in the meta-analysis. There was no association
betweenMDR1 G2677T polymorphism and leukemia risk in
all of five models in overall populations (T vs. G: OR=1.00,
95 % CI=0.88–1.12, P=0.914; TT vs. GG: OR=0.97, 95 %
CI=0.75–1.26, P=0.812; TG vs. GG: OR=1.00, 95 % CI=
0.92–1.08, P=0.939; TT vs. TG/GG: OR=0.98, 95 % CI=
0.67–1.43, P=0.906; TT/TG vs. GG: OR=1.00, 95 % CI=
0.95–1.06, P=0.994). However, the significant association
was found in others (Table 2) under the homozygote model
(TT vs. GG: OR=0.68, 95 % CI=0.48–0.94, P=0.020) and
recessive model (TT vs. TG/GG: OR=0.63, 95 % CI=0.43–
0.92, P=0.016). In the subgroup analysis, according to the
type of leukemia, significant association was found between
MDR1 G2677T polymorphism and myeloid leukemia but not
lymphoblastic leukemia (TT vs. GG: OR=0.66, 95 % CI=
0.46–0.95, P=0.026; TT vs. TG/GG: OR=0.56, 95 % CI=
0.38–0.84, P=0.005). The results suggested that there was no
association between MDR1 G2677T polymorphism and leu-
kemia risk in overall populations, but significant association
was found in others populations (Asians and Africans), and
myeloid leukemia indicated that G2677T polymorphism
might be a protective factor in the susceptibility of myeloid
leukemia and in Asians and Africans.
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Introduction
Leukemia is a type of malignant clonal hematopoietic stem
cell disorder with a bad prognosis due to a range of compli-
cated features, the clonal proliferation of leukemia cells be-
cause of uncontrolled differentiation disorder, disruption and
other mechanisms of apoptosis in the bone marrow, and other
hematopoietic tissues proliferate accumulation and infiltration
of other tissues and organs with inhibition of normal hemato-
poiesis [1]. Leukemia was divided into acute leukemia and
chronic leukemia, according to the speed of onset, while acute
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leukemia can also be subdivided into acute lymphoid leuke-
mia (ALL) and acute myeloid leukemia (AML), according to
cytogenic analysis [2]. ALL is more common in children,
which comprises over 80 % of all acute leukemia. It is esti-
mated that approximately 33.6 in every 1,000,000 children
under 15 years old will develop ALL. However, the etiology
of pediatric ALL remains poorly understood; genetic and
familial factors were proved as risk factors for leukemia
[3–5], while AML is the most common form of acute leuke-
mia in adults as well as in children [6]. It is an extremely
heterogeneous malignant disease resulting from acquired mu-
tations that block the differentiation of primitive hematopoi-
etic cells, accordingly causing immature myeloid precursors
to accumulate, and resulting in an estimated 13,330 cases and
an estimated 8,950 deaths in the USA in 2010 [7]. The
management of AML remains a challenge for hematologists
nowadays [7, 8]. But unfortunately, the exact pathological
mechanism of leukemia is still unclear recently. Previous
studies suggested that a lot of factors were associated with
the susceptibility of leukemia [9–11], and genetic factors have
become the focus of researches [12, 13].
The multidrug resistance gene (MDR1 or ABCB1 ), located
at 7q21.1, its cDNA spans about 4.5 kb, with a core promoter
region and 29 exons ranging in size from 49 to 587 bp, and the
coding region account for less than 5 % of the total [14]. The
MDR1 encodes the membrane transport protein P-
glycoprotein (P-gp), an efflux pump that regulates the exit
and entry of various substrates from the cell. P-gp is expressed
in the intestinal epithelium and affects the disposition and
response of many drugs [15, 16]. At least 50 single-
nucleotide polymorphisms (SNPs) in human MDR1 gene
locus have been reported [14]. The G2677T is the most
common variants in the coding region of MDR1 [17]. The
polymorphism of G2677T was significantly associated with
increased or decreased plasma concentration of P-gp sub-
strates [18, 19]. There were some reports showed that individ-
uals who had the 2677 TT genotype had lower P-gp messen-
ger RNA expression than those who had 2677 GG genotype
[20], while other studies reported an opposite effect of the
2677T mutant allele, namely an increase in transport activity
compared with that of 2677G allele [21], but Tanabe et al. [22]
reported a nonsignificant opposite trend for P-gp expression in
the placenta in relation to the G2677T polymorphism. These
contradictions might be due to the presence of different amino
acids at position 893, which might have different effects on
different drugs [23]. So, the G2677T polymorphism in MDR
gene is one of the important problems in the treatment for
cancer patients with chemotherapy, including leukemia [24].
Many studies have shown the association between MDR1
G2677T polymorphism and the risk of leukemia, but the
results remain inconsistent [25–31]. No prior meta-analysis
is aboutMDR1 G2677T polymorphism and leukemia suscep-
tibility. In order to derive a more precise estimation of the
association between MDR1 G2677T polymorphism and the
risk of leukemia, we carried out this meta-analysis.
Materials and methods
Search strategy
Several electronic databases such as PubMed, Excerpta
Medica Database (Embase), Cochrane Library, and Chinese
Biomedical Literature Database (CBM) are conducted to
search eligible studies about the association of MDR1
G2677T polymorphism and leukemia risk before July 2013
by using the keywords “multidrug resistance gene” or
“MDR1” or “ABCB1” or “rs2032582” in combination with
“polymorphism” or “variation” and “leukemia” or
“leukocythemia” or “leucocythemia.” There were no limita-
tions to the language of publication. The reference lists were
hand-searched to find more relevant publications.
Inclusion and exclusion criteria
The following criteria were used to select the eligible studies:
(a) a case–control study or studies evaluating the association
between theMDR1 G2677T polymorphism and risk of leuke-
mia and (b) the article had to provide sufficient data to estimate
an odds ratio (OR) and 95 % confidence interval (95 % CI).
The following exclusion criteria were used for excluding
studies: (a) studies contained duplicate data, (b) control popu-
lation including patients, and (c) case reports or reviews.
Data extraction
All the data were carefully extracted by the two authors
independently from each publication, according to the inclu-
sion and exclusion criteria listed above. If they encountered
conflicting evaluations, an agreement was reached following a
discussion; if they could not reached to an agreement, a third
author was consulted to resolve the debate. The following
information were extracted: name of the first author, year of
publication, country of origin, ethnicity of the population,
genotyping methods, the Hardy–Weinberg equilibrium
(HWE) of control, type of leukemia, source of the control
group, and the sample size of cases and controls. Different
ethnicities were categorized as Caucasians and Mixed and
Others, and different leukemia types were categorized as
myeloid leukemia (ML) and lymphoblastic leukemia (LL).
Statistical analysis
The strength of the association betweenMDR1 G2677T poly-
morphism and leukemia risk was evaluated by pooled OR
with 95 % CI and calculated to assess according to allele
2192 Tumor Biol. (2014) 35:2191–2197
contrast (T vs. G), homozygote (TT vs. GG), heterozygote
(TG vs. GG), recessive (TT vs. TG/GG), and dominant (TT/
TG vs. GG) models. The significance of the summary ORwas
determined with a Z test and P <0.05 was considered as
statistically significant. The between-study heterogeneity
was assessed by using a chi-square-based Q statistic test. If
the result of the heterogeneity test was P <0.10, it suggests
that between-study heterogeneity existed, and ORs were
pooled by random-effects model (DerSimonian and Laird
method) [32]. Otherwise, the fixed-effects model (the Man-
tel–Haenszel method) was used [33]. Moreover, we also used
I2 value to test the effect of heterogeneity [34]. If obvious
heterogeneity existed (I2 value >50 % or P <0.10), the overall
estimate of risk was calculated by the random-effects model; if
obvious heterogeneity was absent (I2 value <50 % or P >
0.10), then the fixed-effects model was used.
The HWE of controls was tested by using a professional
web-based program (http://ihg2.helmholtz-muenchen.de/
cgibin/hw/hwa1.pl), P >0.05 suggests that the controls
followed HWE balance [35]. Studies with the controls not in
HWE balance were subjected to sensitivity analysis [36].
Sensitivity analysis was used to test the stability of pooled
studies by sequential omission of individual studies. Potential
publication bias was estimated by Egger’s test (P <0.05 was
considered representative of statistically significant
publication bias) [37] and visual observation of funnel plot
[38]. All statistical tests were performed using STATAversion




According to the inclusion criteria defined above, a total of
seven publications including eight studies with 1,229 cases
and 1,097 controls were included in the meta-analysis
[25–31]. The flowchart of the selection of studies for inclusion
in the meta-analysis is shown in Fig. 1d. The study character-
istics included in the meta-analysis were presented in Table 1.
These studies were published between 2005 and 2013. All
publications were written in English, except for one study in
Chinese. Eight independent studies consisted of four Cauca-
sian, two Mix, and two Others (one Asian and one African)
populations. The genotype distributions in the controls of all
the studies included in the meta-analysis were consistent with
HWE (all P >0.05).
Quantitative synthesis of data
Table 2 listed the main results of the meta-analysis of MDR1
G2677T polymorphism and leukemia risk. There was no
association between MDR1 G2677T polymorphism and leu-
kemia risk in all of the five models in overall population (T vs.
G: OR=1.00, 95 % CI=0.88–1.12, P=0.914; TT vs. GG:
OR=0.97, 95 % CI=0.75–1.26, P =0.812; TG vs. GG:
OR=1.00, 95 % CI=0.92–1.08, P=0.939; TT vs. TG/GG:
OR=0.98, 95 % CI=0.67–1.43, P=0.906, Fig. 1a; TT/TG vs.
GG: OR=1.00, 95 % CI=0.95–1.06, P=0.994).
In the subgroup analysis, according to ethnicity, the results
suggested that MDR1 G2677T polymorphism was not asso-
ciated with leukemia risk in Caucasians and Mix population
(Table 2). However, significant association was found in
Others (Table 2) under the homozygote model (TT vs. GG:
OR=0.68, 95 % CI=0.48–0.94, P=0.020) and recessive
model (TT vs. TG/GG: OR=0.63, 95 % CI=0.43–0.92, P=
0.016; Fig. 1c) (Table 2). Because the Others only included
one study that was about Asian and one was about African,
respectively, due to the small sample size, the results are not
representatively significant. In the subgroup analysis, accord-
ing to type of leukemia, significant association was found
between MDR1 G2677T polymorphism and ML but not LL
(TT vs. GG: OR=0.66, 95 % CI=0.46–0.95, P =0.026,
Fig. 1b; TT vs. TG/GG: OR=0.56, 95 % CI=0.38–0.84, P=
0.005).
Heterogeneity analysis and sensitive analysis
As shown in Table 2, there was significance between-study
heterogeneity in the overall population. Therefore, the
random-effect model was utilized to evaluate the relationship
of MDR1 G2677T polymorphism with leukemia risk. There
was substantial heterogeneity among these studies in overall
comparisons. Therefore, we assessed the source of heteroge-
neity by ethnicity and leukemia type, but the heterogeneity
still exists. Sensitivity analysis was used to evaluate the sta-
bility of the overall results by sequentially removing individ-
ual studies. In our meta-analysis, the result of sensitive anal-
ysis shows that no single study could influence the overall
results qualitatively, indicating robustness and reliability of
our results.
Publication bias
Both Begg’s funnel plot and Egger’s test were performed to
assess the publication bias. The shape of the funnel plot did
not suggest any evidence of obvious asymmetry. Similarly, the
results revealed the absence of publication bias (data not
shown).
Discussion
In the present study, to clarify controversial results from previ-
ous reports, we collected all available published studies and
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performed a meta-analysis to examine the association of
MDR1 G2677T polymorphismwith susceptibility to leukemia.
Our meta-analysis showed that no association was found in all
variant genotype carriers. Meanwhile, our data also indicated
that the G2677T polymorphismmight not be a risk factor in the
susceptibility of leukemia. But in subgroup analyses, base on
Fig. 1 a The forest plot describing the meta-analysis under recessive
model for the association between MDR1 G2677T polymorphism and
leukemia risk in overall population (TT vs. TG + GG). b The forest plot
describing the meta-analysis subgroup analysis base on type of leukemia
under recessive model for the association between MDR1 G2677T
polymorphism and leukemia risk (TT vs. TG + GG). c The forest plot
describing the meta-analysis subgroup analysis base on ethnicity under
the homozygous model for the association between MDR1 G2677T
polymorphism and leukemia risk (TT vs. GG). d Flow chart of selection
of studies for inclusion in the meta-analysis
Table 1 General characteristics of studies included in the meta-analysis
First author Year Country Ethnicity Method of genotyping HWE of control Type of leukemia Source of control Sample size
(case/control)
Lv et al. [25] 2012 China Asian PCR 0.11 LL HB 176/170
Elghannam et al. [26] 2013 Egypt African PCR 0.28 ML HB 96/90
Penna et al. [27] 2011 Italy Caucasian PCR 0.45 LL HB 125/125
Vivona et al. [28] 2012 Brazil Mix PCR-RFLP 0.10 ML HB 118/120
Semsei et al. [29] 2008 Hungary Caucasian PCR 0.08 LL HB 375/189
Urayama et al. [30] 2007 USA Mix PCR 0.15 LL HB 294/369
Kaya et al. [31] 2005 Turkey Caucasian PCR-RFLP 0.22 ML PB 28/17
Kaya et al. [31] 2005 Turkey Caucasian PCR-RFLP 0.22 LL PB 17/17
PCR-RFLP PCR-restriction fragment length polymorphism, LL lymphoblastic leukemia, ML myeloid leukemia, HB hospital based, PB population
based
2194 Tumor Biol. (2014) 35:2191–2197
ethnicity and type of leukemia, significant association was
found in Others population and myeloid leukemia (Table 2),
which indicated that G2677T polymorphism might be a pro-
tective factor in the susceptibility of myeloid leukemia in
Asians and Africans. Since only one study was about Asian
and one about African, taking the small sample size into
account, the results are not representatively significant. Con-
clusions should be interpreted with caution.
Previous studies reported that P-gp as a transmembrane
efflux pump for various structurally unrelated anticancer
agents and toxins [14, 39] and a high expression of P-gp on
tumor cells have been shown to correlate with a poor response
to chemotherapy and poor prognosis in cancer patients [40].
Many researchers have investigated the effects of the MDR1
polymorphisms on the development of drug resistance
[41–43]. One of the most important MDR1 gene polymor-
phisms is G2677T SNP. The polymorphism of G2677T was
significantly associated with increased or decreased plasma
concentration of P-gp substrates [18, 19]. There were some
reports showing that individuals who had the 2677 TT geno-
type had lower P-gp messenger RNA expression than those
who had 2677 GG genotype [20], while other studies reported
an opposite effect of the 2677T mutant allele, namely an
increase in transport activity compared with that of 2677G
allele [21], but Tanabe et al. [22] reported a nonsignificant
opposite trend for P-gp expression in the placenta in relation to
the G2677T polymorphism. Therefore, the biological role of
MDR1 polymorphism in carcinogenesis remains unclear. It is
hypothesized that the G2677T may affect the activity of P-gp.
Our study shows that 2677TT genotype inMDR1 gene plays
a protective role in ML patients. This may explain that
2677TT can lead to a low expression of P-gp on ML cells
and increased plasma concentration of P-gp substrates, thus
not causing the resistance to drugs in ML patients.
Table 2 Results of meta-analysis
for MDR1 G2677T polymor-
phism and leukemia risk
OR odds ratio, CI confidence in-
terval, F fixed-effects model, R
random-effects model, ML mye-
loid leukemia, LL Lymphocytic
leukemia
Comparison Population N Test of association Model Test of heterogeneity
OR 95 % CI P P I2
T vs. G Overall 8 1.00 0.88–1.12 0.914 R 0.011 61.6
Caucasians 4 1.13 0.87–1.46 0.377 R 0.029 66.7
Mix 2 1.03 0.92–1.15 0.647 F 0.826 0
Others 2 0.83 0.67–1.03 0.099 R 0.139 54.4
ML 3 0.86 0.73–1.02 0.075 F 0.168 43.9
LL 5 1.04 0.92–1.19 0.510 R 0.042 59.7
TT vs. GG Overall 8 0.97 0.75–1.26 0.812 R 0.020 57.8
Caucasians 4 1.28 0.77–2.13 0.334 R 0.034 64.3
Mix 2 1.01 0.78–1.31 0.922 F 0.268 18.6
Others 2 0.68 0.48–0.94 0.020 F 0.307 4.3
ML 3 0.66 0.46–0.95 0.026 F 0.452 0
LL 5 1.10 0.85–1.42 0.491 R 0.070 53.9
TG vs. GG Overall 8 1.00 0.92–1.08 0.939 F 0.618 0
Caucasians 4 0.97 0.784–1.11 0.642 F 0.433 0
Mix 2 1.05 0.93–1.18 0.447 F 0.162 48.9
Others 2 0.95 0.80–1.11 0.496 F 0.959 0
ML 3 1.08 0.88–1.32 0.477 F 0.250 27.9
LL 5 0.98 0.90–1.07 0.635 F 0.731 0
TT vs. TG/GG Overall 8 0.98 0.67–1.43 0.906 R 0 73.9
Caucasians 4 1.53 0.79–3.39 0.291 R 0.001 80.6
Mix 2 0.88 0.45–1.69 0.691 R 0.101 62.7
Others 2 0.63 0.43–0.92 0.016 F 0.162 48.9
ML 3 0.56 0.38–0.84 0.005 F 0.350 4.7
LL 5 1.19 0.79–1.79 0.411 R 0.004 74.1
TT/TG vs. GG Overall 8 1.00 0.95–1.06 0.994 F 0.748 0
Caucasians 4 1.02 0.93–1.11 0.692 F 0.904 0
Mix 2 1.03 0.94–1.13 0.514 F 0.415 0
Others 2 0.91 0.81–1.03 0.132 F 0.509 0
ML 3 0.98 0.84–1.14 0.792 F 0.243 29.4
LL 5 1.004 0.95–1.07 0.890 F 0.882 0
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The heterogeneity plays an important role in a meta-
analysis, so finding the source of heterogeneity is very impor-
tant for the final result of the meta-analysis. Significant hetero-
geneity was observed in our meta-analysis. We used subgroup
analysis to find the sources of heterogeneity. In the subgroup
analysis by ethnicity, we found heterogeneity still existed in
Caucasians. This may explain that although they have same
genetic background, different individuals have different life-
styles and exposed to different risk factors, and the levels of
exposure to risk factors also differ; this may cause the
heterogeneity. It is possible that other limitations of recruited
studies may partially contribute to the observed heterogene-
ity. For this reason, we conducted analyses using the
random-effects model.
Publication bias is another important aspect which may
have a negative effect on a meta-analysis. In our meta-
analysis, both funnel plot and Egger’s test were used to test
the publication bias of the included studies. As a result, both
the shape of funnel plot and statistical results show no obvious
publication bias; this suggests that the publication bias has
little effect on the results in our study, and the results of our
meta-analysis are relatively stable.
There are remaining some limitations though we con-
ducted comprehensive analysis to show the association
between MDR1 G2677T polymorphism and the risk of
leukemia. First, the number of studies and the number of
samples included in the meta-analysis were relatively
small. Second, only published and written in English and
Chinese studies were included in this meta-analysis, thus,
publication and potential language bias may have occurred,
even though it was not found by making use of the statis-
tical test. Third, subgroup analyses according to age, gen-
der, radiation exposure, and other elements have not been
performed in the study due to insufficient relevant data
available in the primary studies. So, more studies with
larger sample size and providing detailed information
should be performed to assess the effect of MDR1
G2677T polymorphism on leukemia risk.
In conclusion, our meta-analysis systematically analyzed
the association between MDR1 G2677T polymorphism and
the risk of leukemia. The results suggested that there was no
association between MDR1 G2677T polymorphism and leu-
kemia risk in overall population, but significant association
was found in Others population (Asians and Africans) and
myeloid leukemia indicated that G2677T polymorphism
might be a protective factor in the susceptibility of myeloid
leukemia and in Asians and Africans. Considering the limited
sample size and ethnicities included in the meta-analysis,
further large-scaled and well-designed studies are needed to
confirm our results.
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